Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients

被引:1
|
作者
Gomez Rodriguez, Rafael [1 ]
Romero Gutierrez, Marta [1 ]
Gonzalez de Frutos, Concepcion [1 ]
de Artaza Varasa, Tomas [1 ]
de la Cruz Perez, Gema [1 ]
Ciampi Dopazo, Juan Jose [2 ]
Lanciego Perez, Carlos [2 ]
Gomez Moreno, Ana Zaida [2 ]
机构
[1] Complejo Hosp Toledo, Serv Aparato Digestivo, Toledo, Spain
[2] Complejo Hosp Toledo, Serv Radiol Intervencionista, Toledo, Spain
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2011年 / 34卷 / 08期
关键词
Hepatocellular carcinoma; Surveillance; BCLC staging; Treatment; RANDOMIZED CONTROLLED-TRIAL; CHRONIC LIVER-DISEASE; PERCUTANEOUS RADIOFREQUENCY ABLATION; ALPHA-FETOPROTEIN; ETHANOL INJECTION; DIABETES INCREASES; NATURAL-HISTORY; UNITED-STATES; RISK-FACTORS; CIRRHOSIS;
D O I
10.1016/j.gastrohep.2011.06.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is the most frequent cause of mortality in patients with liver cirrhosis. There are no prospective series from a single tertiary hospital in Spain. Material and Methods: We performed a prospective study of patients with HCC in our center. Clinical and epidemiological characteristics, diagnostic method, staging according to the Barcelona Clinic Liver Cancer (BCLC) system and treatment were analyzed. Results: A total of 136 patients were included (80.9% men). The mean age was 66.62 +/- 11.68 years and 91.2% were cirrhotic. Hepatitis C virus (HCV) was the leading cause of liver disease (38.97%). The suspected diagnosis was established by a surveillance program in 63.2%. Noninvasive American Association criteria for the Study of Liver Diseases (AASLD) were the main diagnostic method (73.5%). According to the BCLC, 58.1% were in the early stage (0-A), 21.3% in stage B, 12.5% in stage C and 8.1% in stage D. Early stage patients had followed a surveillance program more frequently than those with non-early stages (79.75% versus 44.35%, p < 0.001). Potentially curative initial treatment was used in 45.58%, the most common treatment being percutaneous ethanol injection (23.13%). Conclusions: Most patients with HCC in our hospital have cirrhosis, the most frequent cause being HCV. HCC surveillance in at-risk patients could increase diagnosis of HCC at an early stage. We achieved an early diagnosis in more than half of cases. The most common initial treatment was percutaneous therapy. (C) 2011 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:524 / 531
页数:8
相关论文
共 50 条
  • [31] Clinical characteristics and outcomes for patients with thymic carcinoma: Evaluation of Masaoka staging
    Litvak, Anna Maria
    Woo, Kaitlin
    Hayes, Sara A.
    Sima, Camelia S.
    Huang, James
    Moreira, Andre L.
    Tsukazan, Maria Teresa Ruiz
    Riely, Gregory J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice
    Celsa, Ciro
    Cerrito, Lucia
    Stella, Leonardo
    Ciccia, Roberta
    Cabibbo, Giuseppe
    Ponziani, Francesca Romana
    HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (02) : 252 - 255
  • [33] Clinical Practice Guideline: The Diagnosis and Treatment of Hepatocellular Carcinoma
    Schneider, Peter
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2014, 111 (26): : 464 - 464
  • [34] Molecular Refinement of Clinical Staging in Hepatocellular Carcinoma Patients Evaluated for Potentially Curative Therapies
    Vitale, Alessandro
    Navaglia, Filippo
    Morales, Rafael Ramirez
    Frigo, Anna Chiara
    Basso, Daniela
    D'Amico, Francesco
    Zanus, Giacomo
    Bonsignore, Pasquale
    Farinati, Fabio
    Burra, Patrizia
    Senzolo, Marco
    Grigoletto, Francesco
    Plebani, Mario
    Cillo, Umberto
    PLOS ONE, 2011, 6 (09):
  • [35] Phenotypes related with the clinical improvement of patients treated with omalizumab in routine clinical practice. Fenoma study
    Campo, P.
    Soto-Campos, J.
    Moreira, A.
    Davila, I
    ALLERGY, 2017, 72 : 9 - 10
  • [36] Clinical characteristics of patients with hepatocellular carcinoma presenting to a single tertiary institute
    Choo, L.
    Morris, D.
    Chu, F.
    Liauw, W.
    Zekry, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 : A279 - A279
  • [37] Treatment of adolescent patients with eating disorders: description of a psychodynamic approach in clinical practice.
    Godart N.
    Atger F.
    Perdereau F.
    Agman G.
    Rein Z.
    Corcos M.
    Jeammet P.
    Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2004, 9 (3) : 224 - 227
  • [38] A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.
    Kobayashi, Kazufumi
    Ogasawara, Sadahisa
    Maruta, Susumu
    Okubo, Tomomi
    Moriguchi, Michihisa
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Kanogawa, Naoya
    Shiko, Yuki
    Inaba, Yosuke
    Nakamura, Kazuyoshi
    Azemoto, Ryosaku
    Ito, Kenji
    Okabe, Shinichiro
    Atsukawa, Masanori
    Itobayashi, Ei
    Ikeda, Masafumi
    Morimoto, Naoki
    Itoh, Yoshito
    Kato, Naoya
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 512 - 512
  • [39] Thalidomide in patients with advanced hepatocellular carcinoma: A clinical/biological study
    Fazio, N.
    Petralia, G.
    Mancuso, P.
    Lorizzo, K.
    Jemos, C.
    Boselli, S.
    Porcu, C.
    Bertolini, F.
    Bellomi, M.
    de Braud, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Prognostic Indicators of Treatment Outcomes in Hepatocellular Carcinoma Patients From Selected Prospective Systemic Clinical Trials
    Khanijow, Vikesh
    Hassan, Manal
    Kaseb, Ahmed
    GASTROENTEROLOGY, 2011, 140 (05) : S185 - S185